Haemostatic Studies in Uraemic Patients Following DDAVP Administration
暂无分享,去创建一个
[1] A. Schwartz,et al. Desmopressin-induced improvement in bleeding times in chronic renal failure patients correlates with platelet serotonin uptake and ATP release. , 1990, The American journal of the medical sciences.
[2] J. Disa,et al. Effect of 1-desamino-8-D-arginine vasopressin (DDAVP) on human platelets. , 1990, Thrombosis research.
[3] W. Hathaway,et al. Use of DDAVP in inherited and acquired platelet dysfunction , 1990, American journal of hematology.
[4] M. Grant,et al. Desmopressin Stimulates Parallel Norepinephrine and Tissue Plasminogen Activator Release in Normal Subjects and Patients with Diabetes Mellitus , 1988, Thrombosis and Haemostasis.
[5] M. Blombäck,et al. DDAVP-induced correction of prolonged bleeding time in patients with congenital platelet function defects. , 1987, Thrombosis research.
[6] J. Ingerslev,et al. The multimeric structure of plasma F VIII:RAg studied by electroelution and immunoperoxidase detection. , 1986, Thrombosis research.
[7] B. Wiman,et al. Determination of tissue plasminogen activator and its "fast" inhibitor in plasma. , 1986, Clinical chemistry.
[8] A. Bloom,et al. The effect of desamino‐D‐arginine vasopressin (DDAVP) and naloxone infusions on factor VIII and possible endothelial cell (EC) related activities , 1984, British journal of haematology.
[9] M. Cheang,et al. SHORTENING OF BLEEDING TIME BY 1-DEAMINO-8-D-ARGININE VASOPRESSIN IN VARIOUS BLEEDING DISORDERS , 1984, The Lancet.
[10] M. Schalekamp,et al. The Inability of Propranolol and Aspirin to Inhibit the Response of Fibrinolytic Activity and Factor VIII-Antigen to Infusion of DDAVP , 1984, Thrombosis and Haemostasis.
[11] P. Mannucci,et al. Effect of Des-Amino-D-Arginine Vasopressin (DDAVP) on Plasma Levels of Platelet and Endothelial Cell Release Products , 1983, Thrombosis and Haemostasis.
[12] G. Remuzzi,et al. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. , 1983, The New England journal of medicine.
[13] P. Mannucci,et al. Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand's disease subtypes , 1982 .
[14] H. J. Olverman,et al. 5‐HYDROXYTRYPTAMINE AND DOPAMINE TRANSPORT BY RAT AND HUMAN BLOOD PLATELETS , 1978, British journal of pharmacology.
[15] P. Mannucci,et al. 1-DEAMINO-8-D-ARGININE VASOPRESSIN: A NEW PHARMACOLOGICAL APPROACH TO THE MANAGEMENT OF HAEMOPHILIA AND VON WILLEBRAND'S DISEASE , 1977, The Lancet.
[16] C. Mielke,et al. The standardized normal Ivy bleeding time and its prolongation by aspirin. , 1969, Blood.
[17] C. Laurell,et al. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. , 1966, Analytical biochemistry.
[18] G. Ashcroft,et al. ESTIMATION OF 5-HYDROXYTRYPTAMINE IN HUMAN BLOOD. , 1964, Clinica chimica acta; international journal of clinical chemistry.
[19] W. Buczko,et al. Study on mechanisms of a haemostatic effect of 1 deamino-8-D-arginine vasopressin (desmopressin) in uraemic patients. , 1990, Folia haematologica.
[20] N. Baumslag. Letter: Lead poisoning. , 1975, Lancet.